Copyright © 2021. Inderes Oyj. All rights reserved.

After Cantargia's CMD last week, the Q1 report offered few surprises. The increased operating loss versus our previous estimate was likely due to R&D investments during the quarter. We make some estimate revisions following the report, owing to an expected increase in spending for the next two years and a somewhat improved outlook for CAN04 following the interim ph II data reported last week. We lower our DCF-based fair valuation range to SEK 45-52 (54-59) per share. Marketing material commissioned by Cantargia.

Lähde: Finwire News

Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer.